CGIP19127 / A021602 / Aram HezelResearch Question:
How well does cabozantinib S-malate work compared with placebo in treating patients
with neuroendocrine tumors that have spread after previous treatment with everolimus?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This randomized phase III trial studies cabozantinib to see how well it works compared
with placebo in treating patients with neuroendocrine or carcinoid tumors that have
spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug
known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors,
that when blocked, may slow tumor growth.
Study Reference #: CGIP19127
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search